MVA p53 vaccine - Tara Immuno-Oncology

Drug Profile

MVA p53 vaccine - Tara Immuno-Oncology

Alternative Names: Modified-Vaccinia-Ankara-p53-vaccine; p53-MVA-vaccine; p53MVA vaccine - Tara Immmuno-Oncology

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; National Cancer Institute (USA)
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer; Solid tumours
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 10 May 2018 MVA p53 vaccine is still in phase I trials for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02275039)
  • 23 Apr 2018 City of Hope Medical Center and National Cancer Institute completes a phase I trial in Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC) (NCT02275039)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Recurrent, Second-line therapy or greater) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top